Back

Septins disruption controls tumor growth and enhances efficacy of Herceptin

Singh, R. K.; Kim, K. K.; Khazan, N.; Rowswell_Turner, R. B.; Laggner, C.; Jones, A.; Srivastava, P.; Hovanesian, V.; Lamere, L.; Conley, T.; Pandita, R.; Baker, C.; Myers, J. R.; Prichett, E.; Awada, A.; Ruffolo, L.; Jackson, C.; Gerber, S.; Ashton, J.; Milano, M. T.; Linehan, D.; Moore, R.

2020-02-20 cancer biology
10.1101/2020.02.19.954529 bioRxiv
Show abstract

Septin expressions are altered in cancer cells and exhibit poor prognoses in malignancies. As the first approach to develop a septin filament targeting agent, we optimized the structure of Forchlorfenuron (FCF), a known plant cytokinin to generate UR214-9, which contrary to FCF, causes septin-2/9 filamental structural catastrophe in cancer cells without altering cellular septin protein levels. In-silico docking using septin-2/septin-2 dimer complex showed that UR214-9 displaced the guanine carbonyl oxygen from the GDP binding domain and showed increased binding energy than FCF(-8.59vs-7.21). UR214-9 reduced cancer cell growth, downregulated HER2/STAT-3 axis and controlled growth of HER2+ pancreatic, breast and ovarian cancer xenografts in NSG mice and enhanced response of Herceptin against HER2+breast cancer xenograft. Transcriptome analysis of UR214-9 exposed cells demonstrated significant perturbation of <20 genes compared to afatinib which impacted >1200 genes in JIMT-1 breast cancer cells indicating target specificity and non-transcriptional functions of UR214-9. In summary, disrupting septins via UR214-9 is a new approach to control the growth of HER2+ malignancies.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.